Yu Tong

Quick links to important sections

Yu Tong

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yu Tong

Quick Facts

Property Description
Active Ingredient Tramadol Hydrochloride
Pharmacological Class Opioid analgesic, Central-acting analgesic
Origin Synthetic substance
Common Use Relief of moderate to moderately severe pain
Forms Tablets, Capsules, Oral drops, Injection solutions

What Type of Medicine is Yu Tong?

Yu Tong is a trade name for a medicine containing the active ingredient Tramadol Hydrochloride, which defines its pharmacological action and classification. The substance is officially categorized as an opioid analgesic within the class of central-acting analgesics. As a synthetic substance, it is manufactured entirely through chemical synthesis rather than being derived from natural opioid sources, giving it a distinct profile. The substance acts as both a mu-opioid receptor agonist and a serotonin/norepinephrine reuptake inhibitor. This dual mechanism is clinically recognized for providing effective pain control that differs from that of traditional single-action opioids.


Tramadol Hydrochloride: Composition and General Purpose

The core composition of Yu Tong is centered entirely around the Tramadol Hydrochloride molecule, making it a single active ingredient product. This medication is formulated into multiple dosage forms, including oral options such as tablets and capsules, and solutions for parenteral administration (injectables). Tramadol is recognized as an essential medicine for its role in controlling pain. The overall purpose of Yu Tong is to serve as an effective analgesic for the management of moderate to moderately severe pain, such as managing recovery-related discomfort following a minor surgical procedure. The availability of diverse forms ensures it can be administered for both acute and sustained pain management needs.

Regulatory References

  1. WHO Model List of Essential Medicines - Tramadol entry
  2. WHO Model List of Essential Medicines

What side effects are possible with Yu Tong?

Possible Side Effects and Safety Information

The official safety profile of Yu Tong (Tramadol Hydrochloride) is structured by classifying documented adverse reactions based on frequency and affected body systems.

Frequency Classification Common Adverse Reactions
Very Common ( ge 1/10 ) Dizziness, Nausea
Common ( ge 1/100 to < 1/10 ) Headache, Somnolence (drowsiness), Vomiting, Constipation, Dry mouth, Hyperhidrosis (sweating), Fatigue

Less frequently reported reactions are classified as Uncommon or Rare and include effects on cardiovascular regulation (e.g., postural hypotension, tachycardia), psychiatric symptoms (e.g., confusion, hallucinations, anxiety), and dermal reactions (e.g., rash, pruritus).


Documented Serious Safety Concerns

The regulatory label highlights several clinically significant, though less common, serious adverse reactions. These include the risk of Serotonin Syndrome, which can occur with use alone or with other serotonergic medicines, and the potential for Seizures (convulsions). The label explicitly notes the risk of Life-Threatening Respiratory Depression, particularly when treatment is initiated or the dose is increased. Other serious documented risks include Severe Hypotension and Anaphylaxis.


Population-Specific Constraints

Safety constraints are defined for specific patient groups. The medicine is contraindicated in children younger than 12 years and in adolescents younger than 18 years following tonsillectomy and/or adenoidectomy. Use is generally not recommended in patients with severe hepatic or renal impairment. Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome.


Regulatory Safety Summary

These official classifications and constraints define the scope of safety considerations for the medicine, distinguishing between expected, high-frequency effects and potentially critical, low-frequency events.

Overdose and Emergency Response

Overdose of Yu Tong (Tramadol Hydrochloride) is officially classified by regulatory authorities as a severe event that can lead to life-threatening or fatal outcomes. Documented overdose manifestations involve significant Central Nervous System (CNS) depression, presenting as profound sedation and coma, along with cardiovascular symptoms such as severe hypotension, circulatory shock, and serious arrhythmias. A core risk documented in regulatory labels is respiratory depression, which can progress to respiratory arrest. The official profile highlights the risk of Serotonin Syndrome and Seizures/Convulsions, with seizures potentially managed by supportive measures like benzodiazepines.

Immediate medical assistance is mandated. Urgent help must be sought when an overdose is suspected, with regulators requiring contact with emergency services or proceeding to an emergency room. The label identifies Naloxone as the specific antidote for opioid-induced respiratory depression, but its administration may only partially antagonize all effects and can increase the risk of seizures. Supportive measures described include re-establishment of a patent airway, assisted ventilation, and management of circulatory function using vasopressors. Population-specific notes warn that accidental ingestion by children, even of a single dose, can result in a fatal overdose, and close monitoring for respiratory depression is required for all individuals.

Therapeutic Uses of Yu Tong

What Yu Tong Treats: Main Uses and Benefits

Yu Tong is generally used for managing symptoms related to physical discomfort classified as moderate to moderately severe. The medication is used in contexts where additional management of discomfort is required. This therapeutic approach is used to help ease the overall symptom burden, which contributes to improved patient comfort.

The medication is commonly used to help with acute pain episodes, discomfort during postoperative recovery, and certain chronic pain syndromes, including persistent musculoskeletal pain and neuropathic pain.

“It is applied in scenarios where additional management of discomfort is required, assisting with maintaining functional stability.”


Support for Acute and Postoperative Discomfort

The medication is considered relevant in clinical settings that involve acute or disruptive symptom patterns, such as significant discomfort after a surgical procedure or resulting from trauma. It may assist with short-term symptom stabilization when symptoms become temporarily overwhelming, supports the patient during difficult episodes by easing distress.


Summary of Symptom Severity: Moderately Severe Pain

Management of Chronic Refractory Pain

Yu Tong may be part of symptomatic management for certain conditions characterized by periods of heightened symptoms that are chronic and ongoing. When applied in these long-term scenarios, it helps address symptom clusters that may become intense or disruptive over time, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Yu Tong — Official Regulatory Information

Yu Tong (Tramadol Hydrochloride) is authorized for use in adults (18+ years), but official regulatory labeling imposes strict constraints based on age, physiological status, and concurrent conditions.


Populations for Whom Use is Contraindicated

Use is absolutely contraindicated in children younger than 12 years of age and in adolescents younger than 18 years for postoperative pain management following tonsillectomy and/or adenoidectomy [2.4, 3.3]. The medicine must not be used in patients with known hypersensitivity to tramadol, significant respiratory depression, acute or severe bronchial asthma, or with known or suspected gastrointestinal obstruction [1.2, 2.4]. Use is also contraindicated in patients with acute intoxication from central nervous system depressants (e.g., alcohol, opioids) or those taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last 14 days [2.1, 2.3].


Age-Related and Condition-Specific Restrictions

Category Regulatory Status Constraint Details
Pediatric Use (12-18 yrs) Restricted/Avoided Adolescents in this age group with risk factors for respiratory compromise (e.g., morbid obesity) should avoid use [2.2, 2.4].
Older Adults (>75 yrs) Use with Caution Patients over 75 years may require special consideration due to the potential for decreased organ function [2.1, 3.7].
Severe Organ Impairment Not Recommended/Avoided Extended-release formulations are not recommended for patients with severe renal impairment or severe hepatic impairment [2.1, 2.8].
Pregnancy and Lactation Restricted/Not Recommended Breastfeeding is not recommended. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS) [3.3].

Regulatory documents define eligibility based on specific physiological and clinical states that increase risk, establishing clear classifications of who is permitted, restricted, or prohibited from using the medicine.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Yu Tong around potential changes in its concentration in the body when co-administered with other medicines that affect its metabolism.


Interaction Categories and Management

Interaction Domain Practical Regulatory Implication
Strong Inhibitors of Metabolism (e.g., CYP3A4 inhibitors) These significantly increase Yu Tong's exposure (AUC). Co-administration requires a mandatory reduction in the Yu Tong dose to avoid excessive systemic levels.
Strong Inducers of Metabolism (e.g., CYP3A4 inducers) These significantly decrease Yu Tong's exposure (AUC). Co-administration with strong inducers is officially required to be avoided due to the risk of reduced effectiveness.
Interference with Laboratory Tests The presence of Yu Tong or its metabolites can interfere with the analytical assays of specific diagnostic tests. This requires careful interpretation of certain lab results.

The established structure of the official interaction profile strictly requires specific actions—either avoidance or dose modification—when combining Yu Tong with strong modulators of the enzyme responsible for its clearance. This approach ensures consistent management of predicted pharmacokinetic alterations. The profile also addresses constraints related to accurate diagnostic procedures by specifying known assay interferences.

Mechanism of Action

Direct mu-Opioid Receptor Activation

This core mechanism involves the active metabolite, O-desmethyltramadol ( M1), which acts as an agonist at the mu-opioid receptor ( OP3) in the spinal cord and brain. This interaction initiates a molecular cascade that effectively hyperpolarizes pain-signaling neurons, inhibiting the release of key neurotransmitters and leading to a reduction in the ascending transmission of signals within the central nervous system.


Modulation of Descending Inhibitory Pathways

A complementary mechanism involves the parent drug weakly inhibiting the reuptake of the neurotransmitters Norepinephrine and Serotonin in the spinal cord. By increasing the synaptic concentration of these monoamines, the drug enhances the activity of the descending inhibitory pathway. This process results in enhanced endogenous inhibition, which contributes synergistically to the drug's overall physiological effect profile.


Mechanistic Constraint and Metabolism

The functional capacity of the mu-opioid component is physiologically constrained by the individual rate of its conversion to the M1 metabolite by the CYP2D6 enzyme. This reliance means the mechanism's full capacity is genetically dependent, and functional constraints, such as reduced enzyme activity, can lead to reduced engagement of the primary receptor target.

Dosage and Administration Information

Administration Overview

Yu Tong (Tramadol Hydrochloride) is administered via both the oral and parenteral routes. Oral forms, including Immediate-Release (IR) tablets and Extended-Release (ER) formulations, may be taken without regard to meals. The parenteral route utilizes solutions for Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection, with IV administration requiring a slow injection rate, typically over one minute.

For the IR formulation, the typical adult starting dose is 50 mg to 100 mg taken every 4 to 6 hours as needed, with the maximum daily dose set at 400 mg. The ER formulation, intended for once-daily dosing, is generally initiated at 100 mg, with a maximum dose of 300 mg.

Standard instructions require that ER tablets must be swallowed whole and must not be crushed, chewed, or split to prevent unintended rapid release of the medicine. Specific dose adjustments are used for patients with severe renal or hepatic impairment, often necessitating an increased dosing interval and a reduced daily maximum dose for the IR product. All forms are administered for the shortest duration necessary, and gradual dose reduction (tapering) is utilized to discontinue the medicine after prolonged use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Yu Tong

Evidence for Use in Acute Pain and Postoperative Discomfort

Research examining the medicine for contexts involving acute, short-term pain, such as after a surgical procedure or an injury, is primarily drawn from short-term, randomized controlled trials (RCTs). These are studies where participants are randomly assigned to receive either Yu Tong, a placebo, or an active comparator drug. Studies examined outcomes related to physical discomfort, mainly monitoring changes in pain intensity scores over a short period. Research exploring short-term symptom changes described patterns where pain intensity metrics were observed to change differently from placebo controls over the initial hours or days of treatment. When studies monitored outcomes against certain other analgesic agents in these acute settings, the measured effects on pain scores sometimes varied compared to the comparator. The consistency of the observed effects across all types of acute pain is not fully established, meaning results apply only to the populations studied.


Evidence for Use in Chronic Pain Syndromes

For contexts involving chronic conditions, such as persistent low back pain, osteoarthritis, or neuropathic pain, the research structure is based on systematic reviews and meta-analyses of randomized trials. These studies explored outcomes related to daily functioning or activity level and monitored changes in pain intensity over short- to medium-term periods. Pooled data from randomized trials reported findings indicating patterns related to average pain scores when compared with placebo controls. Scientific reviews noted that the magnitude of the measured difference frequently fell below the threshold considered a minimal clinically important difference (MCID). Certainty remains low in this chronic pain context due to high variability across the trials, which means that findings were mixed across the full body of evidence.


Long-Term Study Follow-up and Outcomes

Research exploring the effects of Yu Tong over extended periods shows that follow-up durations were limited. The treatment length in the underlying clinical trials typically ranges from 2 to 16 weeks; the longest follow-up for major outcomes is generally around 16 weeks. Evidence indicates that long-term effects are not fully established, and there is limited information for long-term outcomes regarding the medicine's association with symptom patterns over many months or years. Research is ongoing to better characterize durability of response.


What Is Still Uncertain About Yu Tong's Research Record

A primary uncertainty is the low certainty and high heterogeneity observed in the chronic pain trials. Another key limitation noted is the short-term focus of most trials. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes, and evidence quality varies across studies.

Key Studies & References

  1. Tramadol - StatPearls - NCBI Bookshelf (Used for regulatory context, pediatric/elderly cautions, and overall indication framework)

Frequently Asked Questions (FAQ)

Common questions about Yu Tong (FAQ)


Q: Is Yu Tong a generic or brand-name medicine?

The active ingredient in Yu Tong is Tramadol Hydrochloride, which is the established generic name for the substance. Official sources note that this medicine is available globally under various brand names, in addition to being widely available in its generic form.

Q: How quickly does Yu Tong typically start working for its main use?

According to official regulatory documents, the onset of pain relief for the immediate-release oral form typically begins within one hour after administration. The effect generally reaches its maximum or peak effect in approximately two to three hours.

Q: What is the expected timeline to feel the full effects of Yu Tong?

Official clinical pharmacology data indicates that if the immediate-release formulation is taken four times per day, the concentration of the drug and its active metabolite in the blood reaches a stable level, known as steady-state, within approximately two days. This stable concentration is typically considered the appropriate timeframe for assessing the medicine’s expected effect.

Q: Is Yu Tong a controlled substance or does it have a high potential for misuse?

Yes, in the United States, the active ingredient in Yu Tong is officially classified as a Schedule IV controlled substance. Official labeling also includes a Boxed Warning that details the risks of addiction, abuse, and misuse.

Q: How long does Yu Tong stay in your system after the last dose?

Regulatory data from the pharmacokinetics section shows that the medicine's elimination half-life—the time it takes for half of the drug to be removed from the body—is about 6.3 hours for the main drug and about 7.4 hours for its active metabolite. This is based on average population data.

Q: What is the difference between a 'side effect' and an 'adverse reaction' for Yu Tong?

Regulatory documents use both terms to describe unintended physical or mental effects linked to the medicine. Both are formal classifications used by regulators to monitor and categorize all unexpected and undesirable outcomes that occur in patients.

Q: Does taking Yu Tong cause long-term side effects or dependency?

Official labeling includes a Boxed Warning about the risks of addiction, abuse, and misuse, which are risks associated with long-term use. Additionally, official instructions require a gradual dose reduction, or tapering, to stop the medicine after prolonged use, which is a required procedure for medicines associated with developing physical dependence.

Q: Does alcohol consumption affect how Yu Tong works or increase the risk of side effects?

Yes. Official warnings explicitly state that using this medicine at the same time as alcohol may result in profound sedation, respiratory depression, coma, and death. Acute intoxication from central nervous system depressants, including alcohol, is also listed as a contraindication.

Q: Does Yu Tong affect my ability to drive or operate machinery?

Yes. Official warnings advise that the medicine can impair the mental and physical abilities needed to perform potentially hazardous tasks. These tasks include driving a car or operating heavy machinery.

Q: Do regulatory bodies like the FDA or EMA have special warnings about Yu Tong?

Yes. For example, the FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics like Yu Tong. The official label also includes a Boxed Warning that details serious risks, including addiction, abuse, and misuse.

Q: What should I look out for if I'm taking Yu Tong with other prescription medications?

Regulatory documents highlight the need for special caution when the medicine is taken with other serotonergic drugs (due to the risk of Serotonin Syndrome). Caution is also advised with strong inducers or inhibitors of the CYP3A4 and CYP2D6 enzymes, as these can significantly alter the drug's concentration in the body.

Q: Can Yu Tong be taken with common over-the-counter pain relievers like ibuprofen or aspirin?

The regulatory label advises caution regarding the combined use of this medicine with other drugs, especially those that affect the central nervous system or its metabolism. Official documentation indicates that a healthcare provider should be informed of all OTC medicines being taken for a review of potential drug interactions.

Q: Is it safe to use Yu Tong at the same time as cold and flu medicines?

Many cold and flu medicines contain ingredients that can affect the central nervous system or increase the risk of Serotonin Syndrome. Official labeling highlights that the use of Yu Tong with any other CNS depressant or serotonergic medicines is a situation where close monitoring by a healthcare professional is necessary.

Q: What kind of supplements or herbal products have known interactions with Yu Tong?

The regulatory label warns about the use of drugs that are strong inducers or inhibitors of the CYP3A4 and CYP2D6 enzymes, as these may impact the medicine's concentration. Official documentation indicates that a healthcare provider should be informed of all supplements and herbal products being used.

Q: What does the patient information leaflet say about the risk of allergic reactions to Yu Tong?

The regulatory label notes that serious allergic reactions, including anaphylaxis (a severe, life-threatening reaction) and severe dermal reactions like rash or hives, have occurred in patients taking this medicine.

Q: What is the meaning of the [specific term from official text, e.g., 'contraindication'] related to Yu Tong?

A 'contraindication' is a term used in official documents to define a condition or situation for which the use of the medicine is absolutely prohibited. This is because the risk of harm in that situation outweighs any potential benefit.

Q: If I experience a mild side effect from Yu Tong, what general guidance is available?

Official information advises patients to consult a healthcare professional regarding any side effects experienced while taking the medicine.

Q: Can women who are pregnant or planning to become pregnant use Yu Tong?

Official regulatory documents state that prolonged use of this medicine during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn, which may require medical treatment. The use of this drug is generally not recommended during pregnancy or for pain management immediately prior to labor.

Q: Does Yu Tong affect birth control or fertility?

Official documents address the effects on fertility based on nonclinical animal studies. The main prescribing information does not list a universally-cited specific interaction with hormonal birth control.

Q: If I switch to a generic version of Yu Tong, can I expect the exact same effect?

Regulatory bodies authorize generic versions only after they have demonstrated bioequivalence to the original product. Bioequivalence means that the generic product has the same active ingredient, dose, and strength, and is expected to have the same effect in the body.

Q: Is Yu Tong known to cause weight gain or weight loss?

Weight changes are not universally listed as a common or very common adverse reaction in the official regulatory documentation for this medicine.

Q: Do clinical trials of Yu Tong include diverse population groups?

Official regulatory documents include a description of the demographics (e.g., age, sex, race) of the subjects enrolled in the pivotal clinical trials used to establish the drug's safety and effectiveness.

Q: What is the maximum amount of time Yu Tong is typically prescribed for?

The treatment length in the underlying clinical trials typically ranges from 2 to 16 weeks; the longest follow-up for major outcomes is generally around 16 weeks. Evidence regarding long-term outcomes beyond this duration is limited.

Q: What is the general success rate or effectiveness theme of Yu Tong in clinical studies?

Research evidence describes patterns where pain intensity scores were observed to change differently from placebo controls. However, scientific reviews noted that the magnitude of the measured difference frequently fell below the level considered a minimal clinically important difference ( MCID) for chronic pain.

Q: What should I do if I think Yu Tong is not working for me?

Official patient counseling information advises that if the medicine does not control pain, consulting a healthcare provider for an evaluation is appropriate. It also specifies that users should not increase the dose on their own.

Q: Are there any known issues with Yu Tong packaging or administration device (if applicable)?

The regulatory label details constraints for administration, such as the requirement that extended-release tablets must not be crushed or chewed to prevent an unintended rapid release of the medicine.

Q: What patient groups were excluded from the main clinical trials for Yu Tong?

Regulatory documents indicate that certain patient groups who are contraindicated for use were generally excluded from the main efficacy trials. These often include patients with severe hepatic or renal impairment or those taking other drugs with known severe interactions.

How should Yu Tong be stored and disposed of?

How to Store and Dispose of Yu Tong

Official regulatory documents define specific storage and disposal requirements for Yu Tong (Tramadol Hydrochloride) to ensure product stability and safety.

Storage Conditions

The medicine must be stored at a temperature below 30 C and should be protected from both light and moisture. To maintain its labeled stability, the product must be kept in its original container.

Requirement Official Instruction
Temperature Store below 30 C
Protection Protect from light and moisture

Secure Handling and Disposal

Secure storage is mandatory. The product must be kept out of the sight and reach of children, and patients are instructed to store the medicine securely to prevent theft or misuse. For disposal, any unused or expired product must be discarded in accordance with local state guidelines and regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yu Tong found in:

A-Z Index: